Yasushi Ino - Publications

University of Tokyo, Bunkyō-ku, Tōkyō-to, Japan 

39 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Hegazy AM, Yamada D, Kobayashi M, Kohno S, Ueno M, Ali MA, Ohta K, Tadokoro Y, Ino Y, Todo T, Soga T, Takahashi C, Hirao A. Therapeutic strategy for targeting aggressive malignant gliomas by disrupting their energy balance. The Journal of Biological Chemistry. PMID 27519418 DOI: 10.1074/jbc.M116.734756  0.64
2016 Koso H, Yi H, Sheridan P, Miyano S, Ino Y, Todo T, Watanabe S. Identification of RNA-binding protein LARP4B as a tumor suppressor in glioma. Cancer Research. PMID 26933087 DOI: 10.1158/0008-5472.CAN-15-2308  0.64
2014 Takai H, Masuda K, Sato T, Sakaguchi Y, Suzuki T, Suzuki T, Koyama-Nasu R, Nasu-Nishimura Y, Katou Y, Ogawa H, Morishita Y, Kozuka-Hata H, Oyama M, Todo T, Ino Y, et al. 5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex. Cell Reports. 9: 48-60. PMID 25284789 DOI: 10.1016/j.celrep.2014.08.071  0.64
2014 Echizen K, Nakada M, Hayashi T, Sabit H, Furuta T, Nakai M, Koyama-Nasu R, Nishimura Y, Taniue K, Morishita Y, Hirano S, Terai K, Todo T, Ino Y, Mukasa A, et al. PCDH10 is required for the tumorigenicity of glioblastoma cells. Biochemical and Biophysical Research Communications. 444: 13-8. PMID 24406169 DOI: 10.1016/j.bbrc.2013.12.138  0.64
2014 Koyama-Nasu R, Haruta R, Nasu-Nishimura Y, Taniue K, Katou Y, Shirahige K, Todo T, Ino Y, Mukasa A, Saito N, Matsui M, Takahashi R, Hoshino-Okubo A, Sugano H, Manabe E, et al. The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells. Oncogene. 33: 2236-44. PMID 23686309 DOI: 10.1038/onc.2013.168  0.64
2013 Koyama-Nasu R, Nasu-Nishimura Y, Todo T, Ino Y, Saito N, Aburatani H, Funato K, Echizen K, Sugano H, Haruta R, Matsui M, Takahashi R, Manabe E, Oda T, Akiyama T. The critical role of cyclin D2 in cell cycle progression and tumorigenicity of glioblastoma stem cells. Oncogene. 32: 3840-5. PMID 22964630 DOI: 10.1038/onc.2012.399  0.64
2013 Tsuji T, Nakamori M, Iwahashi M, Nakamura M, Ojima T, Iida T, Katsuda M, Hayata K, Ino Y, Todo T, Yamaue H. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. International Journal of Cancer. Journal International Du Cancer. 132: 485-94. PMID 22729516 DOI: 10.1002/ijc.27681  0.64
2012 Koga T, Maruyama K, Tanaka M, Ino Y, Saito N, Nakagawa K, Shibahara J, Todo T. Extended field stereotactic radiosurgery for recurrent glioblastoma. Cancer. 118: 4193-200. PMID 22180028 DOI: 10.1002/cncr.27372  0.64
2011 Ikushima H, Todo T, Ino Y, Takahashi M, Saito N, Miyazawa K, Miyazono K. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. The Journal of Biological Chemistry. 286: 41434-41. PMID 21987575 DOI: 10.1074/jbc.M111.300863  0.64
2011 Watanabe A, Ogiwara H, Ehata S, Mukasa A, Ishikawa S, Maeda D, Ueki K, Ino Y, Todo T, Yamada Y, Fukayama M, Saito N, Miyazono K, Aburatani H. Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 12384-9. PMID 21750150 DOI: 10.1073/pnas.0906930108  0.64
2011 Muraguchi T, Tanaka S, Yamada D, Tamase A, Nakada M, Nakamura H, Hoshii T, Ooshio T, Tadokoro Y, Naka K, Ino Y, Todo T, Kuratsu J, Saya H, Hamada J, et al. NKX2.2 suppresses self-renewal of glioma-initiating cells. Cancer Research. 71: 1135-45. PMID 21169405 DOI: 10.1158/0008-5472.CAN-10-2304  0.64
2010 Ino Y, Todo T. Clinical development of a third-generation oncolytic HSV-1 (G47Δ) for malignant glioma Gene Therapy and Regulation. 5: 101-111. DOI: 10.1142/S1568558610000185  0.64
2010 Ino Y, Todo T. Oncolytic virus therapy for malignant brain tumors Biotherapy. 24: 443-447.  0.64
2009 Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell. 5: 504-14. PMID 19896441 DOI: 10.1016/j.stem.2009.08.018  0.64
2009 Ino Y, Todo T. [Oncolytic virus therapy for malignant brain tumors]. Brain and Nerve = Shinkei KenkyÅ« No Shinpo. 61: 815-22. PMID 19618859  0.64
2009 Koga T, Morita A, Maruyama K, Tanaka M, Ino Y, Shibahara J, Louis DN, Reifenberger G, Itami J, Hara R, Saito N, Todo T. Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. Neuro-Oncology. 11: 446-51. PMID 19164434 DOI: 10.1215/15228517-2008-112  0.64
2009 Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, Miyazono K. Autocrine TGF-β Signaling Maintains Tumorigenicity of Glioma-Initiating Cells through Sry-Related HMG-Box Factors (DOI:10.1016/j.stem.2009.08.018) Cell Stem Cell. 5: 666. DOI: 10.1016/j.stem.2009.11.011  0.64
2006 Ino Y, Saeki Y, Fukuhara H, Todo T. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 643-52. PMID 16428511 DOI: 10.1158/1078-0432.CCR-05-1494  0.64
2005 Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Research. 65: 10663-8. PMID 16322208 DOI: 10.1158/0008-5472.CAN-05-2534  0.64
2005 Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T. High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. The Lancet. Oncology. 6: 953-60. PMID 16321763 DOI: 10.1016/S1470-2045(05)70395-8  0.64
2001 Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. The American Journal of Pathology. 159: 359-67. PMID 11438483 DOI: 10.1016/S0002-9440(10)61702-6  0.64
2001 Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis DN. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 839-45. PMID 11309331  0.64
2000 Tortosa A, Ino Y, Odell N, Swilley S, Sasaki H, Louis DN, Henson JW. Molecular genetics of radiographically defined de novo glioblastoma multiforme. Neuropathology and Applied Neurobiology. 26: 544-52. PMID 11123721 DOI: 10.1046/j.0305-1846.2000.00290.x  0.64
2000 Ino Y, Wahrer DC, Bell DW, Haber DA, Louis DN. Mutation analysis of the hCHK2 gene in primary human malignant gliomas. Neurogenetics. 3: 45-6. PMID 11085597  0.64
2000 Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. International Journal of Radiation Oncology, Biology, Physics. 48: 825-30. PMID 11020580 DOI: 10.1016/S0360-3016(00)00703-3  0.64
2000 Misdraji J, Ino Y, Louis DN, Rosenberg AE, Chiocca EA, Harris NL. Primary lymphoma of peripheral nerve: report of four cases. The American Journal of Surgical Pathology. 24: 1257-65. PMID 10976700 DOI: 10.1097/00000478-200009000-00009  0.64
2000 Cavenee WK. High-grade gliomas with chromosome 1p loss. Journal of Neurosurgery. 92: 1080-1. PMID 10839286  0.64
2000 Ino Y, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, Jhung S, Ramsay DA, von Deimling A, Louis DN, Cairncross JG. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. Journal of Neurosurgery. 92: 983-90. PMID 10839259 DOI: 10.3171/jns.2000.92.6.0983  0.64
2000 Møller MB, Kania PW, Ino Y, Gerdes AM, Nielsen O, Louis DN, Skjødt K, Pedersen NT. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. Leukemia. 14: 898-904. PMID 10803523  0.64
2000 Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Molecular and Cellular Biology. 20: 1436-47. PMID 10648628 DOI: 10.1128/MCB.20.4.1436-1447.2000  0.64
1999 Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE, Louis DN. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. The American Journal of Pathology. 155: 1879-84. PMID 10595918 DOI: 10.1016/S0002-9440(10)65507-1  0.64
1999 Castells A, Ino Y, Louis DN, Ramesh V, Gusella JF, Rustgi AK. Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer. Gastroenterology. 117: 831-7. PMID 10500065 DOI: 10.1016/S0016-5085(99)70341-0  0.64
1999 Ino Y, Silver JS, Blazejewski L, Nishikawa R, Matsutani M, von Deimling A, Louis DN. Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. Journal of Neuropathology and Experimental Neurology. 58: 881-5. PMID 10446812  0.64
1999 Shibui S, Tanaka M, Ino Y, Nomura K, Fujita T. Three-dimensional images by helical CT scan with intra-arterial injection of diluted contrast medium. Japanese Journal of Clinical Oncology. 29: 270-1. PMID 10379341  0.64
1999 Taylor MD, Perry J, Zlatescu MC, Stemmer-Rachamimov AO, Ang LC, Ino Y, Schwartz M, Becker LE, Louis DN, Cairncross JG. The hPMS2 exon 5 mutation and malignant glioma. Case report. Journal of Neurosurgery. 90: 946-50. PMID 10223463 DOI: 10.3171/jns.1999.90.5.0946  0.64
1999 Møller MB, Ino Y, Gerdes AM, Skjødt K, Louis DN, Pedersen NT. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia. 13: 453-9. PMID 10086736  0.64
1998 Stemmer-Rachamimov AO, Ino Y, Lim ZY, Jacoby LB, MacCollin M, Gusella JF, Ramesh V, Louis DN. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. Journal of Neuropathology and Experimental Neurology. 57: 1164-7. PMID 9862639  0.64
1998 Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Journal of the National Cancer Institute. 90: 1473-9. PMID 9776413  0.64
1997 Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita Y, Muramatsu T, Kirino T. Increased expression of midkine during the progression of human astrocytomas. Neuroscience Letters. 233: 29-32. PMID 9324232 DOI: 10.1016/S0304-3940(97)00619-8  0.64
Show low-probability matches.